A Phase I, Ascending Dose Randomized, Blinded, Placebo-Controlled, Single-Center Study to evaluate the safety and tolerability of of Intravenous FDY-5301 in healthy volunteers

Trial Profile

A Phase I, Ascending Dose Randomized, Blinded, Placebo-Controlled, Single-Center Study to evaluate the safety and tolerability of of Intravenous FDY-5301 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs FDY 5301 (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 17 May 2017 Status changed from recruiting to completed.
    • 23 Sep 2016 Status changed from not yet recruiting to recruiting, as per Faraday Pharmaceuticals media release.
    • 07 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top